Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
Department of Cardiovascular Sciences, Cardiovascular Research Centre, NIHR Leicester Biomedical Research Centre University of Leicester, Leicester, United Kingdom.
Int J Cardiol. 2019 Feb 1;276:212-217. doi: 10.1016/j.ijcard.2018.11.094. Epub 2018 Nov 17.
BACKGROUND: Aortic valve stenosis (AVS) and coronary artery disease (CAD) have a significant genetic contribution and commonly co-exist. To compare and contrast genetic determinants of the two diseases, we investigated associations of the LPA and 9p21 loci, i.e. the two strongest CAD risk loci, with risk of AVS. METHODS: We genotyped the CAD-associated variants at the LPA (rs10455872) and 9p21 loci (rs1333049) in the GeneCAST (Genetics of Calcific Aortic STenosis) Consortium and conducted a meta-analysis for their association with AVS. Cases and controls were stratified by CAD status. External validation of findings was undertaken in five cohorts including 7880 cases and 851,152 controls. RESULTS: In the meta-analysis including 4651 cases and 8231 controls the CAD-associated allele at the LPA locus was associated with increased risk of AVS (OR 1.37; 95%CI 1.24-1.52, p = 6.9 × 10) with a larger effect size in those without CAD (OR 1.53; 95%CI 1.31-1.79) compared to those with CAD (OR 1.27; 95%CI 1.12-1.45). The CAD-associated allele at 9p21 was associated with a trend towards lower risk of AVS (OR 0.93; 95%CI 0.88-0.99, p = 0.014). External validation confirmed the association of the LPA risk allele with risk of AVS (OR 1.37; 95%CI 1.27-1.47), again with a higher effect size in those without CAD. The small protective effect of the 9p21 CAD risk allele could not be replicated (OR 0.98; 95%CI 0.95-1.02). CONCLUSIONS: Our study confirms the association of the LPA locus with risk of AVS, with a higher effect in those without concomitant CAD. Overall, 9p21 was not associated with AVS.
背景:主动脉瓣狭窄(AVS)和冠状动脉疾病(CAD)具有显著的遗传贡献,并且通常同时存在。为了比较和对比这两种疾病的遗传决定因素,我们研究了 LPA 和 9p21 位点(即两个最强的 CAD 风险位点)与 AVS 风险的关联。
方法:我们在 GeneCAST(Genetics of Calcific Aortic STenosis)联盟中对 LPA(rs10455872)和 9p21 位点(rs1333049)的 CAD 相关变体进行了基因分型,并对其与 AVS 的关联进行了荟萃分析。病例和对照按 CAD 状态分层。在包括 7880 例病例和 851152 例对照的五个队列中进行了发现的外部验证。
结果:在包括 4651 例病例和 8231 例对照的荟萃分析中,LPA 位点的 CAD 相关等位基因与 AVS 风险增加相关(OR 1.37;95%CI 1.24-1.52,p=6.9×10),在无 CAD 的患者中效应更大(OR 1.53;95%CI 1.31-1.79)与 CAD 患者相比(OR 1.27;95%CI 1.12-1.45)。9p21 的 CAD 相关等位基因与 AVS 风险降低呈趋势相关(OR 0.93;95%CI 0.88-0.99,p=0.014)。外部验证证实了 LPA 风险等位基因与 AVS 风险的关联(OR 1.37;95%CI 1.27-1.47),在无 CAD 的患者中,其效应更大。9p21 CAD 风险等位基因的微小保护作用无法复制(OR 0.98;95%CI 0.95-1.02)。
结论:我们的研究证实了 LPA 位点与 AVS 风险的关联,在无合并 CAD 的患者中,其效应更高。总体而言,9p21 与 AVS 无关。
Cell Mol Biol (Noisy-le-grand). 2019-7-31
Thromb Haemost. 2014-5-5
N Engl J Med. 2013-2-7
CJC Open. 2024-6-11
Genes (Basel). 2024-10-10
Int J Mol Sci. 2022-11-4
Handb Exp Pharmacol. 2022
Curr Atheroscler Rep. 2020-1-7
Nat Commun. 2018-3-7
Eur Heart J. 2017-9-21
J Am Coll Cardiol. 2017-3-28
Arterioscler Thromb Vasc Biol. 2016-12
J Clin Endocrinol Metab. 2016-9
N Engl J Med. 2015-8-20